Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Christian W. Mandl · TIBA BIOTECH, LLC · 2022 · $300,000 — This proposal is to develop a high potency, low-dose Powassan virus (POWV) RNA vaccine candidate using Tiba Biotech’s innovative replicon RNA delivery system. As the geographical range of ticks grows due to climate change, the incidence of Tickborne Diseases such as POWV is expected to increase, pos…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2022 · $788,448 — Abstract A vaccine for prevention of genital herpes is a high public health priority. Herpes vaccines that performed well in rodents have not protected humans; therefore, novel approaches are needed. We propose the following: 1) Set a much higher bar for vaccine efficacy in animal models than used p…
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2022 · $577,515 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Luis J Sigal · THOMAS JEFFERSON UNIVERSITY · 2022 · $195,000 — Summary Prevention of morbidity and mortality from viral infections and of complications from live-virus vaccine immunizations requires the identification of genes that confer natural resistance to viruses. Ectromelia virus (ECTV), the agent of mousepox, is a natural pathogen of the mouse. When ECT…
Christopher S Anderson · UNIVERSITY OF ROCHESTER · 2022 · $101,672 — Respiratory Syncytial Virus (RSV) is the second leading cause of hospitalization in children worldwide and has been increasing appreciated as a cause of hospitalization and death in the elderly. Recent studies have shown that polyvalent vaccine formulations, mixture of antigens derived from distinct…
Gundeep Singh Dhillon · STANFORD UNIVERSITY · 2022 · $455,592 — PROJECT SUMMARY / ABSTRACT Lung transplantation (LT) recipients suffer from life-threatening pulmonary infections that can trigger acute rejection and death. Although vaccination is the most effective way for preventing infections, vaccine efficacy is limited in immunocompromised solid organ transpl…
Donna L. Farber · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $820,875 — PROJECT SUMMARY Immune system development during infancy and childhood sets the stage for a lifetime of protective immunity. Infants and children are known to be more susceptible to ubiquitous respiratory and mucosal pathogens for which adults have prior exposures. However, our recent experience in …
MEGERDITCH KILEDJIAN · RUTGERS, THE STATE UNIV OF N.J. · 2022 · $365,086 — RNA 5′ end capping provides a layer of “epitranscriptomic” regulation, influencing numerous aspects of RNA fate, including stability, processing, localization and translatability. Furthermore, enzymes that remove RNA 5′ end caps play critical roles in modulating these processes. Recently, a previous…
David M Koelle · UNIVERSITY OF WASHINGTON · 2022 · $558,757 — Project Summary: The waning of immunity has a major impact on morbidity and mortality in the aged. Antigen-specific, acquired, and especially T-cellular is important in host defense against chronic intracellular pathogens and cancer. Infections with these microbes and skin cancers with high mutation…
Xiaoting Zhang · RNA NANOTHERAPEUTICS LLC · 2022 · $406,500 — Project Summary Breast cancer is one of the most frequent cancers and leading causes of death for women in the U.S. with an estimated 287,850 new diagnoses of invasive breast cancer and 43,250 deaths in 2022. The vast majority (75%) of breast cancer is estrogen receptor-positive (ER+) breast cancer …
Milka Koupenova · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2022 · $418,750 — PROJECT SUMMARY Influenza infection increases the incidence of acute MI (AMI) within the first 7 days after detection and the therapeutic benefit of vaccination is comparable to current therapies for secondary prevention of AMI. Platelets are the blood component central to thrombosis and uncontroll…
Christian W. Mandl · TIBA BIOTECH, LLC · 2022 · $284,906 — Project Summary The proposal is to develop an RNA-based, rapid-response influenza vaccine prototype, supporting NIAID’s call for nucleic acid-based vaccines that protect against pandemic influenza threats. Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate. The virus…
Judith S. Currier · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $7,007,011 — Abstract: With the global COVID-19 pandemic, we recognize a significant need for vaccines that modify COVID-19 in SARS-CoV-2 infected individuals. Addressing this gap, the National Institutes of Health (NIH) led rapid constitution of the CoVPN, partnering 5 NIH supported clinical trial networks, to …
Laura Su · UNIVERSITY OF PENNSYLVANIA · 2023 · $602,727 — Project Summary An ongoing outbreak of a novel coronavirus infection (COVID-19) has claimed millions of lives and disrupted social infrastructures around the world. Fortunately, the new mRNA vaccines from Moderna or Pfizer/BioNTech are highly effective against SARS-CoV-2. However, much remains unkno…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2023 · $850,346 — PROJECT SUMMARY A central goal in HIV/AIDS vaccine research is the elicitation of broadly neutralizing antibodies (bNAbs). Here, we propose to leverage three recent discoveries from our groups to generate novel envelope (Env) immunogens that target the V1V2 region of the trimer…
Dennis A Bente · THOMAS JEFFERSON UNIVERSITY · 2023 · $788,347 — Crimean-Congo hemorrhagic fever virus (CCHFV) causes severe disease in humans, with fatality rates reaching 40%. CCHFV is endemic to parts of Africa, Asia, the Middle East, and Europe, specifically to regions where the tick vector, species of the Hyalomma genus, is present. Classified as an NIH/NIAI…
Elias Sayour · UNIVERSITY OF FLORIDA · 2023 · $531,320 — Project Summary Immunotherapy has shown profound benefit for adult patients but has yet to be fully unlocked for pediatric solid tumors such as osteosarcoma (OSA) where a significant percentage of children/adolescents succumb due to the presence of lung metastasis. OSA, like many poorly tumor immuno…
JAY PONDER · WASHINGTON UNIVERSITY · 2023 · $312,196 — PROJECT SUMMARY/ABSTRACT Nucleic acids (NAs) are the major information carrying molecules of life. The ability to use computation to model the structure, dynamic and interactions of DNA and RNA is a key adjunct to experimental study of these biomolecules. For example, pseudouridine-containing mRNA v…
Robbie B Mailliard · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2023 · $758,692 — ABSTRACT The CDC recommends that persons living with HIV (PWH) be vaccinated against SARS-CoV-2. However, there are minimal scientific data to support this important public health principle in relation to ongoing immune dysfunction and chronic comorbidities and the persistent HIV reservoir in antire…
NASSER Khaled ALTORKI · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $1,098,880 — Overall Component: Project Summary/Abstract The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an est…